Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry
Oliver Gautschi(Université Toulouse III - Paul Sabatier), Alexander Drilon(Memorial Sloan Kettering Cancer Center), Daniel D. Karp(The University of Texas MD Anderson Cancer Center), Isabelle Monnet(Ente Ospedaliero Cantonale), Joachim Diebold(University of Lucerne), Benjamin Besse(Institut Gustave Roussy), Julie Milia(Université Fédérale de Toulouse Midi-Pyrénées), Nir Peled(Shaare Zedek Medical Center), Joel W. Neal(Stanford Medicine), Robert C. Doebele(Aurora University), Heather A. Wakelee(Palo Alto Institute), David R. Gandara(University of California, Davis), Sebastian Michels(University Hospital Cologne), Martin Früh(University of Bern), Sanjay Popat(Royal Marsden NHS Foundation Trust), Pasi A. Jänne(Harvard University), Jin‐Yuan Shih(National Taiwan University Hospital), Vignhesh Narayanan(Ente Ospedaliero Cantonale), J. Remon-Masip(Ente Ospedaliero Cantonale), James Chih‐Hsin Yang(National Taiwan University Hospital), Julien Mazières(Université Toulouse III - Paul Sabatier), David P. Carbone(Vanderbilt University), Gérard Zalcman(Inserm), Tony Mok(Chinese University of Hong Kong), Vamsidhar Velcheti(Cleveland Clinic), R. Rosell(Instituto Oncológico Dr. Rosell), Florian Cabillic(Ente Ospedaliero Cantonale), Kristin Zeidler(Ente Ospedaliero Cantonale), Georg Pall(University Hospital Innsbruck), Patrizia Froesch(Institute of Oncology Research), Jonathan W. Riess(University of California Davis Medical Center), D. Ross Camidge(University of Colorado Denver), Niki Karachaliou(Institut Català d'Oncologia), Thomas Muley(German Center for Lung Research), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Dwight H. Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Juergen Wolf(Ente Ospedaliero Cantonale), Arne Warth(Heidelberg University), Thomas Filleron(Institut universitaire du cancer de Toulouse Oncopole), Michael Van Den Heuvel(Ente Ospedaliero Cantonale), Sacha I. Rothschild(University Hospital of Basel)
Cited by 357
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k